Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pioglitazone influence of triglyceride accumulation in the myocardium in diabetes

Trial Profile

Pioglitazone influence of triglyceride accumulation in the myocardium in diabetes

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Nov 2014

At a glance

  • Drugs Pioglitazone (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms PIRAMID
  • Most Recent Events

    • 16 Sep 2011 Results of an analysis that focused on plasma omentin levels presented at the 47th Annual Meeting of the European Association for the Study of Diabetes.
    • 29 Jun 2010 Effects of pioglitazone on plasma cholesteryl ester transfer protein (CETP) mass have been presented at the 70th Annual Scientific Sessions of the American Diabetes Association.
    • 01 Jan 2010 Effects on pericardial fat volume have been published in the Journal of Clinical Endocrinology and Metabolism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top